Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Dabigatran Etexilate Tablet with Rabeprazole
NCT03143166Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dabigatran etexilate oral solution in Atrial fibrillation (AFib) and venous thromboembolism (VTE), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point of Total Dabigatran at 48 hours and Maximum Concentration of Total Dabigatran in Plasma at 48 hours. Started May 2017; status: completed.
02
Drugs
dabigatran etexilate oral solution
03
Conditions
Atrial fibrillation (AFib)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03143166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03143166.